Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: Results from the German AIO KRK-0104 trial

British Journal of Cancer

Volumn 105, Issue 2, 2011, Pages 206-211

  Stintzing, S ^a   Fischer Von Weikersthal, L ^b   Vehling Kaiser, U ^c   Stauch, M ^d   Hass, H G ^e   Dietzfelbinger, H ^f   Oruzio, D ^g   Klein, S ^h   Zellmann, K ⁱ   Decker, T ^f   Schulze, M ^j   Abenhardt, W ^k   Puchtler, G ^l   Kappauf, H ^m   Mittermuller J ⁿ   Haberl, C ^o   Giessen, C ^a   Moosmann, N ^a   Heinemann, V ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b St Marien Hospital   (Germany)

^c Onkologische Praxis   (Germany)

^d Onkologische Praxis   (Germany)

^e MARIENHOSPITAL STUTTGART   (Germany)

^f Schlossberg Klinik ^*  (Germany)

^g Central Klinikum   (Germany)

^h Klinikum   (Germany)

ⁱ Schlossberg Klinik   (Germany)

^j Onkologische Praxis   (Germany)

^k Onkologische Praxis MPO   (Germany)

^l Klinikum   (Germany)

^m Onkologische Praxis   (Germany)

ⁿ Onkologische Praxis   (Germany)

^o Klinikum   (Germany)

more..

Author keywords

capecitabine; cetuximab; colorectal cancer; skin toxicity

Indexed keywords

CAPECITABINE; CETUXIMAB; IRINOTECAN; OXALIPLATIN;

ARTICLE; CLINICAL ASSESSMENT; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE CONTROL; DRUG EFFICACY; HAND FOOT SYNDROME; HUMAN; MAJOR CLINICAL STUDY; METASTATIC COLORECTAL CANCER; MULTIPLE CYCLE TREATMENT; NAIL; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN TOXICITY;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; GERMANY; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; SKIN DISEASES; TREATMENT OUTCOME;

EID: 79960232266     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.227     Document Type: Article

References (24)

1. Abushullaih S, Saad ED, Munsell M, Hoff PM (2002) Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience. Cancer Invest 20(1): 3-10 (Pubitemid 34151055)
2. Bajetta E, Di Bartolomeo M, Mariani L, Cassata A, Artale S, Frustaci S, Pinotti G, Bonetti A, Carreca I, Biasco G, Bonaglia L, Marini G, Iannelli A, Cortinovis D, Ferrario E, Beretta E, Lambiase A, Buzzoni R (2004) Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. Cancer 100(2): 279-287 (Pubitemid 38063635)
3. Borner M, Koeberle D, Von Moos R, Saletti P, Rauch D, Hess V, Trojan A, Helbling D, Pestalozzi B, Caspar C, Ruhstaller T, Roth A, Kappeler A, Dietrich D, Lanz D, Mingrone W (2008) Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK. Ann Oncol 19(7): 1288-1292 (Pubitemid 351911959)
4. Cassidy J, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzen F, Saltz L (2008) Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 26(12): 2006-2012
5. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351(4): 337-345 (Pubitemid 38944402)
6. Diasio RB (2002) An evolving role for oral fluoropyrimidine drugs. J Clin Oncol 20(4): 894-896 (Pubitemid 34141829)
7. Diaz-Rubio E, Tabernero J, Gomez-Espana A, Massuti B, Sastre J, Chaves M, Abad A, Carrato A, Queralt B, Reina JJ, Maurel J, Gonzalez-Flores E, Aparicio J, Rivera F, Losa F, Aranda E (2007) Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. J Clin Oncol 25(27): 4224-4230 (Pubitemid 47548562)
8. Gressett SM, Stanford BL, Hardwicke F (2006) Management of hand-foot syndrome induced by capecitabine. J Oncol Pharm Pract 12(3): 131-141 (Pubitemid 44696441)
9. Haller DG, Cassidy J, Clarke SJ, Cunningham D, Van Cutsem E, Hoff PM, Rothenberg ML, Saltz LB, Schmoll HJ, Allegra C, Bertino JR, Douillard JY, Gustavsson BG, Milano G, O'Connell M, Rustum Y, Tabernero J, Gilberg F, Sirzen F, Twelves C (2008) Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol 26(13): 2118-2123
10. Heo YS, Chang HM, Kim TW, Ryu MH, Ahn JH, Kim SB, Lee JS, Kim WK, Cho HK, Kang YK (2004) Hand-foot syndrome in patients treated with capecitabine- containing combination chemotherapy. J Clin Pharmacol 44(10): 1166-1172 (Pubitemid 39202461)
11. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, Tebbutt NC, van Hazel G, Wierzbicki R, Langer C, Moore MJ (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357(20): 2040-2048 (Pubitemid 350106711)
12. Kang YK, Lee SS, Yoon DH, Lee SY, Chun YJ, Kim MS, Ryu MH, Chang HM, Lee JL, Kim TW (2010) Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study. J Clin Oncol 28(24): 3824-3829
13. Koopman M, Antonini NF, Douma J, Wals J, Honkoop AH, Erdkamp FL, de Jong RS, Rodenburg CJ, Vreugdenhil G, Loosveld OJ, van Bochove A, Sinnige HA, Creemers GJ, Tesselaar ME, Slee PH, Werter MJ, Mol L, Dalesio O, Punt CJ (2007) Sequential vs combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 370(9582): 135-142 (Pubitemid 47042893)
14. Lassere Y, Hoff P (2004) Management of hand-foot syndrome in patients treated with capecitabine (Xeloda). Eur J Oncol Nurs 8(Suppl 1): S31-S40 (Pubitemid 39194085)
15. Milano G, Etienne-Grimaldi MC, Mari M, Lassalle S, Formento JL, Francoual M, Lacour JP, Hofman P (2008) Candidate mechanisms for capecitabine-related hand-foot syndrome. Br J Clin Pharmacol 66(1): 88-95 (Pubitemid 351822156)
16. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H (1998) Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34(8): 1274-1281 (Pubitemid 28342121)
17. Moosmann N, von Weikersthal LF, Vehling-Kaiser U, Stauch M, Hass HG, Dietzfelbinger H, Oruzio D, Klein S, Zellmann K, Decker T, Schulze M, Abenhardt W, Puchtler G, Kappauf H, Mittermuller J, Haberl C, Schalhorn A, Jung A, Stintzing S, Heinemann V (2011) Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104-a randomized trial of the German AIO CRC Study Group. J Clin Oncol 29(8): 1050-1058
18. Porschen R, Arkenau HT, Kubicka S, Greil R, Seufferlein T, Freier W, Kretzschmar A, Graeven U, Grothey A, Hinke A, Schmiegel W, Schmoll HJ (2007) Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol 25(27): 4217-4223 (Pubitemid 47548561)
19. Rea DW, Nortier JW, Ten Bokkel Huinink WW, Falk S, Richel DJ, Maughan T, Groenewegen G, Smit JM, Steven N, Bakker JM, Semiond D, Kerr DJ, Punt CJ (2005) A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer. Ann Oncol 16(7): 1123-1132 (Pubitemid 41418315)
20. Schuller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, Utoh M, Mori K, Weidekamm E, Reigner B (2000) Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 45(4): 291-297 (Pubitemid 30151522)
21. Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, Erdkamp FL, Vos AH, van Groeningen CJ, Sinnige HA, Richel DJ, Voest EE, Dijkstra JR, Vink-Borger ME, Antonini NF, Mol L, van Krieken JH, Dalesio O, Punt CJ (2009) Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360(6): 563-572
22. Tol J, Koopman M, Rodenburg CJ, Cats A, Creemers GJ, Schrama JG, Erdkamp FL, Vos AH, Mol L, Antonini NF, Punt CJ (2008) A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. Ann Oncol 19(4): 734-738 (Pubitemid 351461045)
23. Twelves C, Scheithauer W, McKendrick J, Nowacki M, Seitz J, Van Hazel G, Wong A, Diaz-Rubio E, Gilberg F, Cassidy J (2008) Capecitabine vs 5-FU/LV in stage III colon cancer: updated 5-year efficacy data from X-ACT trial and preliminary analysis of relationship between hand-foot syndrome (HFS) and efficacy. ASCO 2008 Gastrointestinal Cancers Symposium abstract 274
24. Wolf SL, Qin R, Menon SP, Rowland Jr KM, Thomas S, Delaune R, Christian D, Pajon Jr ER, Satele DV, Berenberg JL, Loprinzi CL (2010) Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5. J Clin Oncol 28(35): 5182-5187